{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T19:41:12Z","timestamp":1792611672759,"version":"4.5.0"},"reference-count":94,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004755","name":"EMD Serono","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004755","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000801","name":"Bayer HealthCare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000801","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.msard.2020.102538","type":"journal-article","created":{"date-parts":[[2020,10,7]],"date-time":"2020-10-07T04:15:10Z","timestamp":1602044110000},"page":"102538","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"special_numbering":"C","title":["Review of approved NMO therapies based on mechanism of action, efficacy and long-term effects"],"prefix":"10.1016","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3713-8890","authenticated-orcid":false,"given":"Staley A.","family":"Brod","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"14","key":"10.1016\/j.msard.2020.102538_bib0001","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1212\/WNL.0b013e3182a6cb5c","article-title":"Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica","volume":"81","author":"Jiao","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2020.102538_bib0002","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1742-2094-9-14","article-title":"Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients","volume":"9","author":"Jarius","year":"2012","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.msard.2020.102538_bib0003","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jns.2017.11.022","article-title":"Evaluation of comorbidities and health care resource use among patients with highly active neuromyelitis optica","volume":"384","author":"Ajmera","year":"2018","journal-title":"J Neurol Sci"},{"issue":"Pt 6","key":"10.1016\/j.msard.2020.102538_bib0004","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1093\/brain\/aws109","article-title":"Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan","volume":"135","author":"Kitley","year":"2012","journal-title":"Brain"},{"issue":"4","key":"10.1016\/j.msard.2020.102538_bib0005","doi-asserted-by":"crossref","first-page":"e468","DOI":"10.1212\/NXI.0000000000000468","article-title":"Mortality in neuromyelitis optica is strongly associated with African ancestry","volume":"5","author":"Mealy","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"4","key":"10.1016\/j.msard.2020.102538_bib0006","doi-asserted-by":"crossref","first-page":"e580","DOI":"10.1212\/NXI.0000000000000580","article-title":"Neuromyelitis optica spectrum disorder: patient experience and quality of life","volume":"6","author":"Beekman","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"24","key":"10.1016\/j.msard.2020.102538_bib0007","doi-asserted-by":"crossref","first-page":"e2265","DOI":"10.1212\/WNL.0000000000006645","article-title":"Nationwide prevalence and incidence study of neuromyelitis optica spectrum disorder in Denmark","volume":"91","author":"Papp","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2020.102538_bib0008","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.msard.2018.12.011","article-title":"Long-term disability in neuromyelitis optica spectrum disorder with a history of myelitis is associated with age at onset, delay in diagnosis\/preventive treatment, MRI lesion length and presence of symptomatic brain lesions","volume":"28","author":"Mealy","year":"2019","journal-title":"Mult Scler Relat Disord"},{"issue":"5","key":"10.1016\/j.msard.2020.102538_bib0009","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1212\/WNL.53.5.1107","article-title":"The clinical course of neuromyelitis optica (Devic\u2019s syndrome)","volume":"53","author":"Wingerchuk","year":"1999","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.msard.2020.102538_bib0010","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S1474-4422(07)70216-8","article-title":"The spectrum of neuromyelitis optica","volume":"6","author":"Wingerchuk","year":"2007","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.msard.2020.102538_bib0011","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/B978-0-444-63432-0.00021-9","article-title":"Autoimmune AQP4 channelopathies and neuromyelitis optica spectrum disorders","volume":"133","author":"Hinson","year":"2016","journal-title":"Handb Clin Neurol"},{"issue":"6","key":"10.1016\/j.msard.2020.102538_bib0012","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1177\/1352458514551454","article-title":"Idiopathic aquaporin-4 antibody negative longitudinally extensive transverse myelitis","volume":"21","author":"Hyun","year":"2015","journal-title":"Mult Scler"},{"issue":"12","key":"10.1016\/j.msard.2020.102538_bib0013","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1111\/ene.12679","article-title":"Neuromyelitis optica: a positive appraisal of seronegative cases","volume":"22","author":"Bernard-Valnet","year":"2015","journal-title":"Eur J Neurol."},{"issue":"4","key":"10.1016\/j.msard.2020.102538_bib0014","doi-asserted-by":"crossref","first-page":"e134","DOI":"10.1212\/NXI.0000000000000134","article-title":"Update on biomarkers in neuromyelitis optica","volume":"2","author":"Melamed","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.msard.2020.102538_bib0015","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.msard.2018.07.025","article-title":"MOG antibody disease: a review of MOG antibody seropositive neuromyelitis optica spectrum disorder","volume":"25","author":"Narayan","year":"2018","journal-title":"Mult Scler Relat Disord"},{"issue":"2","key":"10.1016\/j.msard.2020.102538_bib0016","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1177\/1352458516663853","article-title":"The impact of 2015 neuromyelitis optica spectrum disorders criteria on diagnostic rates","volume":"23","author":"Hamid","year":"2017","journal-title":"Mult Scler."},{"issue":"5","key":"10.1016\/j.msard.2020.102538_bib0017","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/ana.24617","article-title":"Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrum","volume":"79","author":"Flanagan","year":"2016","journal-title":"Ann Neurol."},{"issue":"2","key":"10.1016\/j.msard.2020.102538_bib0018","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0304-3940(00)01364-1","article-title":"Presence of aquaporin-4 and muscarinic receptors in astrocytes and ependymal cells in rat brain: a clue to a common function?","volume":"292","author":"Badaut","year":"2000","journal-title":"Neurosci Lett."},{"key":"10.1016\/j.msard.2020.102538_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/S1095-6433(00)80225-1","article-title":"Aquaporins and water homeostasis in the central nervous system","author":"Amiry-Moghaddam","year":"2000","journal-title":"Comparative Biochemistry and Physiology, Part A124"},{"issue":"12","key":"10.1016\/j.msard.2020.102538_bib0020","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1080\/14728222.2017.1398236","article-title":"The aquaporin-4 water channel as a potential drug target in neurological disorders","volume":"21","author":"Verkman","year":"2017","journal-title":"Expert Opin. Ther. Targets"},{"issue":"7","key":"10.1016\/j.msard.2020.102538_bib0021","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1001\/archneur.63.7.964","article-title":"Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression","volume":"63","author":"Pittock","year":"2006","journal-title":"Arch Neurol."},{"issue":"4","key":"10.1016\/j.msard.2020.102538_bib0022","article-title":"Corticosteroids or ACTH for acute exacerbations in multiple sclerosis","author":"Filippini","year":"2000","journal-title":"Cochrane Database Syst Rev."},{"issue":"1","key":"10.1016\/j.msard.2020.102538_bib0023","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1177\/1352458506071174","article-title":"Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica","volume":"13","author":"Watanabe","year":"2007","journal-title":"Mult Scler."},{"issue":"6","key":"10.1016\/j.msard.2020.102538_bib0024","doi-asserted-by":"crossref","first-page":"e504","DOI":"10.1212\/NXI.0000000000000504","article-title":"Apheresis therapies for NMOSD attacks: a retrospective study of 207 therapeutic interventions","volume":"5","author":"Kleiter","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"4","key":"10.1016\/j.msard.2020.102538_bib0025","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1177\/1352458513495938","article-title":"Role of intravenous immunoglobulin in the treatment of acute relapses of neuromyelitis optica: experience in 10 patients","volume":"20","author":"Elsone","year":"2014","journal-title":"Mult Scler."},{"issue":"19","key":"10.1016\/j.msard.2020.102538_bib0026","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1212\/01.wnl.0000260970.63493.c8","article-title":"Idiopathic transverse myelitis: corticosteroids, plasma exchange, or cyclophosphamide","volume":"68","author":"Greenberg","year":"2007","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.msard.2020.102538_bib0027","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1001\/archneurol.2010.203","article-title":"Neuromyelitis optica treatment: analysis of 36 patients","volume":"67","author":"Bichuetti","year":"2010","journal-title":"Arch Neurol."},{"issue":"4","key":"10.1016\/j.msard.2020.102538_bib0028","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1212\/WNL.51.4.1219","article-title":"Devic\u2019s neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine","volume":"51","author":"Mandler","year":"1998","journal-title":"Neurology."},{"issue":"9","key":"10.1016\/j.msard.2020.102538_bib0029","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1001\/archneurol.2009.175","article-title":"Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients","volume":"66","author":"Jacob","year":"2009","journal-title":"Arch Neurol."},{"issue":"7","key":"10.1016\/j.msard.2020.102538_bib0030","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1212\/01.WNL.0000159399.81861.D5","article-title":"An open label study of the effects of rituximab in neuromyelitis optica","volume":"64","author":"Cree","year":"2005","journal-title":"Neurology."},{"issue":"11","key":"10.1016\/j.msard.2020.102538_bib0031","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1001\/archneur.65.11.noc80069","article-title":"Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients","volume":"65","author":"Jacob","year":"2008","journal-title":"Arch Neurol."},{"issue":"9","key":"10.1016\/j.msard.2020.102538_bib0032","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1001\/archneurol.2011.103","article-title":"Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis","volume":"68","author":"Clifford","year":"2011","journal-title":"Arch Neurol."},{"issue":"10","key":"10.1016\/j.msard.2020.102538_bib0033","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1007\/s00415-015-7852-y","article-title":"Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability","volume":"262","author":"Zephir","year":"2015","journal-title":"J Neurol."},{"issue":"9","key":"10.1016\/j.msard.2020.102538_bib0034","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1001\/jamaneurol.2013.3071","article-title":"A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder","volume":"70","author":"Kim","year":"2013","journal-title":"JAMA Neurol."},{"issue":"15","key":"10.1016\/j.msard.2020.102538_bib0035","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1212\/WNL.0b013e3182152881","article-title":"Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab","volume":"76","author":"Pellkofer","year":"2011","journal-title":"Neurology."},{"issue":"11","key":"10.1016\/j.msard.2020.102538_bib0036","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1001\/jamaneurol.2016.1637","article-title":"Efficacy and Safety of Rituximab Therapy in Neuromyelitis Optica Spectrum Disorders: a Systematic Review and Meta-analysis","volume":"73","author":"Damato","year":"2016","journal-title":"JAMA Neurol."},{"issue":"1","key":"10.1016\/j.msard.2020.102538_bib0037","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12883-019-1261-2","article-title":"Effectiveness of rituximab in neuromyelitis optica: a meta-analysis","volume":"19","author":"Gao","year":"2019","journal-title":"BMC Neurol"},{"issue":"1\u20132","key":"10.1016\/j.msard.2020.102538_bib0038","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jns.2012.02.017","article-title":"Variable results after rituximab in neuromyelitis optica","volume":"317","author":"Lindsey","year":"2012","journal-title":"J Neurol Sci."},{"issue":"2","key":"10.1016\/j.msard.2020.102538_bib0039","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.nrl.2012.03.014","article-title":"The effect of intravenous immunoglobulin on neuromyelitis optica","volume":"28","author":"Magraner","year":"2013","journal-title":"Neurologia."},{"issue":"9","key":"10.1016\/j.msard.2020.102538_bib0040","doi-asserted-by":"crossref","first-page":"969","DOI":"10.2169\/internalmedicine.52.7885","article-title":"Efficacy of intravenous cyclophosphamide therapy for neuromyelitis optica spectrum disorder","volume":"52","author":"Yaguchi","year":"2013","journal-title":"Intern Med."},{"issue":"4","key":"10.1016\/j.msard.2020.102538_bib0041","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1001\/archneurol.2010.322","article-title":"Efficacy and safety of mitoxantrone in patients with highly relapsing neuromyelitis optica","volume":"68","author":"Kim","year":"2011","journal-title":"Arch Neurol."},{"issue":"7","key":"10.1016\/j.msard.2020.102538_bib0042","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1001\/archneur.63.7.957","article-title":"Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease)","volume":"63","author":"Weinstock-Guttman","year":"2006","journal-title":"Arch Neurol."},{"issue":"3","key":"10.1016\/j.msard.2020.102538_bib0043","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1212\/NXI.0000000000000034","article-title":"Massive CNS monocytic infiltration at autopsy in an alemtuzumab-treated patient with NMO","volume":"1","author":"Gelfand","year":"2014","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"2","key":"10.1016\/j.msard.2020.102538_bib0044","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1001\/archneurol.2011.216","article-title":"Failure of natalizumab to prevent relapses in neuromyelitis optica","volume":"69","author":"Kleiter","year":"2012","journal-title":"Arch Neurol."},{"issue":"16","key":"10.1016\/j.msard.2020.102538_bib0045","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1212\/WNL.0b013e3181f8832e","article-title":"IFNbeta-1b may severely exacerbate Japanese optic-spinal MS in neuromyelitis optica spectrum","volume":"75","author":"Shimizu","year":"2010","journal-title":"Neurology."},{"issue":"2","key":"10.1016\/j.msard.2020.102538_bib0046","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1177\/1352458506070732","article-title":"Immunosuppressive therapy is more effective than interferon in neuromyelitis optica","volume":"13","author":"Papeix","year":"2007","journal-title":"Mult Scler."},{"issue":"1","key":"10.1016\/j.msard.2020.102538_bib0047","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1177\/1352458511431973","article-title":"Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder","volume":"18","author":"Min","year":"2012","journal-title":"Mult Scler."},{"issue":"7","key":"10.1016\/j.msard.2020.102538_bib0048","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1001\/jamaneurol.2015.0533","article-title":"Long-term Therapy With Interleukin 6 Receptor Blockade in Highly Active Neuromyelitis Optica Spectrum Disorder","volume":"72","author":"Ringelstein","year":"2015","journal-title":"JAMA Neurol."},{"issue":"15","key":"10.1016\/j.msard.2020.102538_bib0049","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1212\/WNL.0000000000000317","article-title":"Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study","volume":"82","author":"Araki","year":"2014","journal-title":"Neurology."},{"issue":"1","key":"10.1016\/j.msard.2020.102538_bib0050","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/cr.2009.139","article-title":"Complement and its role in innate and adaptive immune responses","volume":"20","author":"Dunkelberger","year":"2010","journal-title":"Cell Res."},{"issue":"11","key":"10.1016\/j.msard.2020.102538_bib0051","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/nrneph.2012.195","article-title":"STEC-HUS, atypical HUS and TTP are all diseases of complement activation","volume":"8","author":"Noris","year":"2012","journal-title":"Nat Rev Nephrol."},{"key":"10.1016\/j.msard.2020.102538_bib0052","doi-asserted-by":"crossref","unstructured":"52 Hill A., Kelly R.J., Hillmen P. Thrombosis in paroxysmal nocturnal hemoglobinuria. 1392-1397. 2013;121(25):4985\u20134996; quiz 5105.","DOI":"10.1182\/blood-2012-09-311381"},{"issue":"2","key":"10.1016\/j.msard.2020.102538_bib0053","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1177\/1352458516688352","article-title":"Neuromyelitis optica spectrum disorder diagnostic criteria: sensitivity and specificity are both important","volume":"23","author":"Wingerchuk","year":"2017","journal-title":"Mult Scler."},{"issue":"5","key":"10.1016\/j.msard.2020.102538_bib0054","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1002\/ana.24630","article-title":"In vivo imaging reveals rapid astrocyte depletion and axon damage in a model of neuromyelitis optica-related pathology","volume":"79","author":"Herwerth","year":"2016","journal-title":"Ann Neurol."},{"issue":"3","key":"10.1016\/j.msard.2020.102538_bib0055","doi-asserted-by":"crossref","first-page":"273","DOI":"10.3390\/ijms17030273","article-title":"The Immunology of Neuromyelitis Optica-Current Knowledge, Clinical Implications, Controversies and Future Perspectives","volume":"17","author":"Jasiak-Zatonska","year":"2016","journal-title":"Int J Mol Sci."},{"issue":"3","key":"10.1016\/j.msard.2020.102538_bib0056","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/WCO.0000000000000551","article-title":"Mechanisms for lesion localization in neuromyelitis optica spectrum disorders","volume":"31","author":"Bradl","year":"2018","journal-title":"Curr. Opin. Neurol."},{"issue":"3","key":"10.1016\/j.msard.2020.102538_bib0057","doi-asserted-by":"crossref","first-page":"e104","DOI":"10.1212\/NXI.0000000000000104","article-title":"B lymphocytes in neuromyelitis optica","volume":"2","author":"Bennett","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"10.1016\/j.msard.2020.102538_bib0058","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.3389\/fimmu.2018.01941","article-title":"T Cell\/B Cell Collaboration and Autoimmunity: an Intimate Relationship","volume":"9","author":"Petersone","year":"2018","journal-title":"Front Immunol."},{"issue":"1","key":"10.1016\/j.msard.2020.102538_bib0059","doi-asserted-by":"crossref","first-page":"e311","DOI":"10.1212\/NXI.0000000000000311","article-title":"Effects of neuromyelitis optica-IgG at the blood-brain barrier in vitro","volume":"4","author":"Takeshita","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"issue":"9","key":"10.1016\/j.msard.2020.102538_bib0060","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/j.biocel.2012.06.013","article-title":"Neuromyelitis optica: aquaporin-4 based pathogenesis mechanisms and new therapies","volume":"44","author":"Ratelade","year":"2012","journal-title":"Int J Biochem Cell Biol."},{"issue":"1","key":"10.1016\/j.msard.2020.102538_bib0061","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1038\/s41467-020-16625-7","article-title":"Transcriptomics and proteomics reveal a cooperation between interferon and T-helper 17 cells in neuromyelitis optica","volume":"11","author":"Agasing","year":"2020","journal-title":"Nat Commun."},{"issue":"9","key":"10.1016\/j.msard.2020.102538_bib0062","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1136\/jnnp-2018-317969","article-title":"CSF cytokine profile in MOG-IgG+ neurological disease is similar to AQP4-IgG+ NMOSD but distinct from MS: a cross-sectional study and potential therapeutic implications","volume":"89","author":"Kaneko","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"10.1016\/j.msard.2020.102538_bib0063","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder","author":"Pittock","year":"2019","journal-title":"N Engl J Med."},{"key":"10.1016\/j.msard.2020.102538_bib0064","doi-asserted-by":"crossref","DOI":"10.1080\/14728214.2020.1803828","article-title":"Emerging drugs for the treatment of neuromyelitis optica","author":"Duchow","year":"2020","journal-title":"Expert Opin Emerg Drugs."},{"key":"10.1016\/j.msard.2020.102538_bib0065","doi-asserted-by":"crossref","unstructured":"65 Nishimoto N., Terao K., Mima T., Nakahara H., Takagi N., Kakehi T. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. 1392-1397. 2008;112(10):3959\u20133964.","DOI":"10.1182\/blood-2008-05-155846"},{"issue":"3","key":"10.1016\/j.msard.2020.102538_bib0066","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1385\/CRIAI:28:3:231","article-title":"Clinical study of tocilizumab in children with systemic-onset juvenile idiopathic arthritis","volume":"28","author":"Yokota","year":"2005","journal-title":"Clin Rev Allergy Immunol"},{"issue":"9617","key":"10.1016\/j.msard.2020.102538_bib0067","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0140-6736(08)60453-5","article-title":"Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial","volume":"371","author":"Smolen","year":"2008","journal-title":"Lancet."},{"key":"10.1016\/j.msard.2020.102538_bib0068","series-title":"Antihuman IL-6 Receptor Antibody","first-page":"151","author":"Nishimoto","year":"2008"},{"issue":"9","key":"10.1016\/j.msard.2020.102538_bib0069","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1358\/dot.2006.42.9.1025692","article-title":"Tocilizumab: blockade of interleukin-6 signaling pathway as a therapeutic strategy for inflammatory disorders","volume":"42","author":"Paul-Pletzer","year":"2006","journal-title":"Drugs Today (Barc)."},{"issue":"4","key":"10.1016\/j.msard.2020.102538_bib0070","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrd2863","article-title":"Tocilizumab","volume":"8","author":"Scheinecker","year":"2009","journal-title":"Nature reviews Drug discovery."},{"issue":"4","key":"10.1016\/j.msard.2020.102538_bib0071","doi-asserted-by":"crossref","first-page":"827","DOI":"10.3109\/s10165-012-0715-9","article-title":"Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab","volume":"23","author":"Araki","year":"2013","journal-title":"Mod Rheumatol."},{"issue":"22","key":"10.1016\/j.msard.2020.102538_bib0072","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","article-title":"Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder","volume":"381","author":"Yamamura","year":"2019","journal-title":"N Engl J Med."},{"key":"10.1016\/j.msard.2020.102538_bib0073","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2019.10.1109","article-title":"Efficacy of satralizumab as monotherapy in pre-specified subgroups of SAkuraStar, a double-blind placebo-controlled phase 3 clinical study in patients with neuromyelitis optica spectrum\u00a0 disorder (NMOSD)","author":"Bennett","year":"2019","journal-title":"J Neuro Sci."},{"key":"10.1016\/j.msard.2020.102538_bib0074","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(19)31817-3","article-title":"Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial","author":"Cree","year":"2019","journal-title":"Lancet."},{"key":"10.1016\/j.msard.2020.102538_bib0075","series-title":"5th annual Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum","article-title":"The N-MOmentum study \u2013 a randomized, placebo-controlled, double-blind trial of inebilizumab for neuromyelitis optica spectrum disorder: randomized controlled period and open-label extension results","author":"Cree","year":"2020"},{"key":"10.1016\/j.msard.2020.102538_bib0076","unstructured":"76 www.ocrelizumabinfo.com. Ocrelizumab and COVID-19 Pharmacovigilance Data. https:\/\/www.ocrelizumabinfo.com\/content\/dam\/gene\/ocrelizumabinfo\/pdfs\/covid-19-pharmacovigilance-data.pdf. Published 2020. Accessed."},{"key":"10.1016\/j.msard.2020.102538_bib0077","doi-asserted-by":"crossref","DOI":"10.1177\/1756286418761697","article-title":"B cell-based therapies in CNS autoimmunity: differentiating CD19 and CD20 as therapeutic targets","volume":"11","author":"Forsthuber","year":"2018","journal-title":"Ther Adv Neurol Disord."},{"issue":"1","key":"10.1016\/j.msard.2020.102538_bib0078","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s13311-015-0402-6","article-title":"Anti-B-Cell Therapies in Autoimmune Neurological Diseases: rationale and Efficacy Trials","volume":"13","author":"Alexopoulos","year":"2016","journal-title":"Neurotherapeutics."},{"issue":"4","key":"10.1016\/j.msard.2020.102538_bib0079","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1093\/brain\/awy010","article-title":"Condition-dependent generation of aquaporin-4 antibodies from circulating B cells in neuromyelitis optica","volume":"141","author":"Wilson","year":"2018","journal-title":"Brain."},{"issue":"1","key":"10.1016\/j.msard.2020.102538_bib0080","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s13311-012-0162-5","article-title":"Hematopoietic stem cell therapy for multiple sclerosis: top 10 lessons learned","volume":"10","author":"Atkins","year":"2013","journal-title":"Neurotherapeutics."},{"issue":"7","key":"10.1016\/j.msard.2020.102538_bib0081","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S1474-4422(08)70138-8","article-title":"Autologous haematopoietic stem-cell transplantation in multiple sclerosis","volume":"7","author":"Mancardi","year":"2008","journal-title":"Lancet Neurol"},{"issue":"22","key":"10.1016\/j.msard.2020.102538_bib0082","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1212\/WNL.0000000000003987","article-title":"Autologous hematopoietic stem cell transplantation in multiple sclerosis: a meta-analysis","volume":"88","author":"Sormani","year":"2017","journal-title":"Neurology."},{"issue":"7","key":"10.1016\/j.msard.2020.102538_bib0083","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.jocn.2015.02.007","article-title":"Resolution of aquaporin-4 antibodies in a woman with neuromyelitis optica treated with human autologous stem cell transplant","volume":"22","author":"Aouad","year":"2015","journal-title":"J Clin Neurosci."},{"issue":"6","key":"10.1016\/j.msard.2020.102538_bib0084","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/NRL.0b013e3181b126e3","article-title":"A preliminary result of treatment of neuromyelitis optica with autologous peripheral hematopoietic stem cell transplantation","volume":"16","author":"Peng","year":"2010","journal-title":"Neurologist."},{"issue":"2","key":"10.1016\/j.msard.2020.102538_bib0085","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1177\/1352458514541978","article-title":"Autologous hematopoietic stem cell transplantation in neuromyelitis optica: a registry study of the EBMT Autoimmune Diseases Working Party","volume":"21","author":"Greco","year":"2015","journal-title":"Mult Scler."},{"issue":"5","key":"10.1016\/j.msard.2020.102538_bib0086","doi-asserted-by":"crossref","first-page":"e276","DOI":"10.1212\/NXI.0000000000000276","article-title":"Restoring immune tolerance in neuromyelitis optica: part I","volume":"3","author":"Steinman","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"issue":"5","key":"10.1016\/j.msard.2020.102538_bib0087","doi-asserted-by":"crossref","first-page":"e277","DOI":"10.1212\/NXI.0000000000000277","article-title":"Restoring immune tolerance in neuromyelitis optica: part II","volume":"3","author":"Bar-Or","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"issue":"6","key":"10.1016\/j.msard.2020.102538_bib0088","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1038\/bmt.2009.305","article-title":"Autologous haematopoietic stem cell transplantation for secondary progressive multiple sclerosis: an exploratory cost-effectiveness analysis","volume":"45","author":"Tappenden","year":"2010","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.msard.2020.102538_bib0089","doi-asserted-by":"crossref","first-page":"410","DOI":"10.3389\/fimmu.2018.00410","article-title":"Regenerating Immunotolerance in Multiple Sclerosis with Autologous Hematopoietic Stem Cell Transplant","volume":"9","author":"Massey","year":"2018","journal-title":"Front Immunol."},{"key":"10.1016\/j.msard.2020.102538_bib0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.101967","article-title":"In MS: immunosuppression is passe","volume":"40","author":"Brod","year":"2020","journal-title":"Mult Scler Relat Disord."},{"issue":"12","key":"10.1016\/j.msard.2020.102538_bib0091","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1136\/annrheumdis-2015-207841","article-title":"Opportunistic infections and biologic therapies in immune-mediated inflammatory diseases: consensus recommendations for infection reporting during clinical trials and postmarketing surveillance","volume":"74","author":"Winthrop","year":"2015","journal-title":"Ann Rheum Dis."},{"issue":"3","key":"10.1016\/j.msard.2020.102538_bib0092","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N Engl J Med."},{"key":"10.1016\/j.msard.2020.102538_bib0093","unstructured":"93 OCREVUS PI-. 2020."},{"issue":"Suppl 2","key":"10.1016\/j.msard.2020.102538_bib0094","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/j.cmi.2018.02.003","article-title":"ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52)","volume":"24","author":"Mikulska","year":"2018","journal-title":"Clin Microbiol Infect."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482030612X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482030612X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:55:38Z","timestamp":1761900938000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221103482030612X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":94,"alternative-id":["S221103482030612X"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2020.102538","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Review of approved NMO therapies based on mechanism of action, efficacy and long-term effects","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2020.102538","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102538"}}